Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The Canadian patent expands the company’s intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This news matters because it strengthens Greenland Mines’ position in the emerging field of gene therapy for neurodegenerative diseases, which affect millions worldwide. The patent coverage in Canada, a key market for pharmaceutical development, provides a competitive edge and potential revenue streams through licensing or future product sales. For leaders in business and technology, this signals that the company is building a robust IP foundation that could attract partnerships or investment.
Greenland Mines operates two divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project; and Biotech, including Klotho’s KLTO-202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.
The implications for the industry are significant. If KLTO-101 and KLTO-202 prove effective, they could offer new treatment options for debilitating conditions with high unmet need. The patent also positions Greenland Mines to potentially license the technology to larger pharmaceutical companies or pursue its own clinical trials. For investors, the expansion of IP protection reduces risk and enhances the value of the company’s biotech assets.
For more details, the full press release is available at https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
